Serepta Therapeutics ($SRPT) finalized the sale of its Rare Pediatric Disease Priority Review Voucher for $125 million. The voucher is being sold to a subsidiary of Gilead Sciences. Serepta received the voucher along with the FDA approval of EXONDYS 51. The voucher allows for accelerated review of a future marketing application.
Emergent BioSolutions ($EBS) has modified its contract with the U.S. Government's Biomedical Advanced Research and Development Authority (BARDA).The modification will allow future filling and deliveries of its botulism antitoxin, BAT [Botulism Antitoxin Heptavalentt (A,B,C,D,E,F,G)-(Equine)] to the Strategic National Stockpile. The value of the modification is expected to be nearly $53 million over a period of five years.